<DOC>
	<DOCNO>NCT00866762</DOCNO>
	<brief_summary>The aim present study evaluate efficacy safety MK-0683 treatment PV ET . This agent recently show potent inhibitor autonomous proliferation haematopoietic cell PV ET patient carry JAK2 V617F mutation . Accordingly , may anticipate MK-0683 - decrease JAK2 allele burden - may influence clonal myeloproliferation vivo granulocyte , platelet endothelial activation , consider major determinant morbidity mortality ( thrombosis , bleeding , extramedullary haematopoiesis , myelofibrosis ) disorder . The effect MK-0683 molecular level study global/ focus gene expression profiling , epigenome profiling proteomics .</brief_summary>
	<brief_title>A Study Efficacy MK-0683 Patients With Polycythaemia Vera Essential Thrombocythaemia</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Male female patient &gt; 18 year age AND A confirm diagnosis PV AND Biochemical evidence active disease define : need phlebotomy within last 3 month leukocyte count &gt; 10 x 10^9/L absence infection inflammation ( normal CRP ) and/or ( PV/ET ) platelet count &gt; 450 x 10^9/L absence infection inflammation ( normal CRP ) ( PV/ET ) OR Male female patient &gt; 18 year age AND A confirm diagnosis ET AND Biochemical evidence active disease define *a platelet count &gt; 450 x 10^9/L absence infection inflammation Inclusion Criteria PV ET : Newly diagnose previously treat patient chronic phase OR Advanced phase PV ET define blast &gt; 1 x 10^9/L peripheral blood and/or white cell count &gt; 30 x 10^9/L OR Resistant refractory PV ET define haemoglobin &lt; 10.5 gm/dl platelet count &gt; 600 x 10^9/L current therapy OR Cycling platelet count therapy OR Intolerant therapy define patient PV ET side effect current therapy prevent continuation ( leg ulcer hydroxycarbamide , unacceptable fatigue etc interferon ) A platelet count &gt; 1500 x 10^9/L ( need cytoreduction platelet count ) Patients childbearing potential without negative pregnancy test prior initiation study drug Women breast feeding Males females use contraceptive sexually active . EGOC Performance status Score &gt; = 3 Serum creatinine 2 x 's teh ULN Total serum bilirubin 1.5 x 's ULN Serum AST/ALT 3 x 's ULN Interferon alpha within 1 week day 1 Hydroxycarbamide within 1 week day 1 Anagrelide within 1 week day 1 Valproic acid ( anticonvulsant ) within 28 day day 1 Any investigational drug within 28 day day 1 Active HIV , HBV HCV infection Any serious concomitant disease circumstance could limit compliance study , include limited following : CTCAE grade 34 cardiac general &amp; arrhythmia , psychiatric social condition may interfere patient compliance . Any prior malignancy exception cervical intraepithelial neoplasia , basal cell carcinoma skin , localized malignancy undergone potentially curative therapy evidence disease five year , deem low risk recurrence his/her treat physician . Patient know allergy hypersensitivity study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Polycythaemia Vera</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Essential Thrombocythaemia</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>HDAC-inhibitor</keyword>
	<keyword>Haematology</keyword>
	<keyword>Hematology</keyword>
	<keyword>Haematological disorder</keyword>
	<keyword>Haematological disease</keyword>
	<keyword>Hematological disorder</keyword>
	<keyword>Hematological disease</keyword>
</DOC>